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Urinary C5b-9 excretion and clinical course in idiopathic human
membranous nephropathy. Recent reports suggested that the presence of
terminal complement complex (C5b-9) in urine from patients with idio-
pathic membranous nephropathy (IMN) may indicate on-going immuno-
logical damage. This report documents the relationship between C5b-9
excretion and clinical outcome in 35 adult patients with biopsy-proven
IMN and progressively declining renal function. There were two groups of
patients. Group I received one of three treatment regimens: prednisolone
alone, prednisolone and chlorambucil, or prednisolonc and cyclophospha-
mide (N = 22). Group II received no immunosuppressive therapy (N =
17). Three of the 18 patients receiving immunosuppressive drugs had more
than one treatment regimen as they experienced a clinical relapse during
the study period; hence 22 treatments were available for analysis. Urine
samples were collected regularly and urinary C5b-9 (uC5b-9) was deter-
mined by ELISA. Both groups were similar with respect to age, sex
distribution, and the duration of follow-up. An improvement in protein-
uria and creatinine clearance was noted in the immunosuppressed group.
Thirty-five patients were excreting C5b-9 initially (18 from group I and 17
from group II); 17 patients continued to excrete C5b-9 at the end of the
observation period. These 17 patients had a significantly worse clinical
outcome when compared to the 18 patients whose C5b-9 excretion became
negative, either spontaneously or with treatment (P < 0.005). These
results indicate that continuing C5b-9 excretion is correlated with a poor
clinical outcome. They also suggest that uC5b-9 is a dynamic marker of
ongoing immunological injury, and therefore may be useful in the initial
assessment and monitoring of patients with IMN and in identifying
patients who may derive benefit from immunosuppressive therapy.
Human idiopathic membraneous nephropathy (IMN) is the
most common cause of adult-onset nephrotic syndrome in West-
ern societies [1]. Many patients with IMN go into spontaneous
and lasting remission, particularly if they only have mild protein-
uria and never develop hypoalbuminemia and/or edema. Never-
theless, this condition is associated with considerable morbidity
and mortality: between 20% and 50% of IMN patients with a
nephrotic syndrome will reach end-stage renal failure (ESRF)
within 10 years of diagnosis [2]. In view of this variable prognosis
and since IMN is almost certainly an immunologically mediated
disorder, a number of studies, both controlled and uncontrolled,
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have reported upon the efficacy of intervention with immunosup-
pressive drugs. Most of these studies, variably employing glu-
cocorticoids and cytotoxic drugs either alone or in combination,
have dealt with patients with a well-maintained glomerular filtra-
tion rate (GFR) [3—8]. The results have been inconsistent and
there is still no universally accepted regimen employed in the
treatment of such patients. Indeed, some authorities still recom-
mend that intervention with immunosuppressive drugs is not
indicated at all in patients with well preserved GFR [9]. Far fewer
studies have been reported of patients in whom renal function is
declining progressively [10—13]. These reports have also been
conflicting, although there is a growing consensus among clini-
cians that many, if not all, such patients warrant an attempt to
preserve, or even improve, residual GFR by the institution of
immunosuppressive drug regimens, provided that no other cause
for functional decline such as renal vein thrombosis [14], diuretic-
induced interstitial nephritis [15] or coincident anti-glomerular
basement membrane (GBM) disease [161 can be demonstrated.
In all the studies, whether with a stable or declining GFR, the
missing parameter is undoubtedly the ability to monitor on-going
immunological insult with a readily detectable marker in blood or
urine. The detection (and possibly the quantification) of such a
marker could prove valuable in a number of ways. It could: (i)
indicate on-going immunological damage even in the presence of
a stable GFR, treatment of which with immunosuppressive drugs
may potentially prevent subsequent functional impairment; (ii)
indicate on-going immunological (as opposed to non-immunolog-
ical) damage as the cause of declining GFR, which again may be
responsive to immunosuppressive treatment; and (iii) be used as
a mechanism to tailor the dose and duration of any immunosup-
pressive protocol in an individual patinet.
Recently, we and others have reported a number of studies that
suggest that the presence of the terminal complement activation,
the C5b-9 complex, in the urine of patients with IMN [17, 181 and
in animals with the laboratory counterpart Heymann nephritis
[19], reflects persisting immunological injury. Furthermore, in
patients with initially well maintained GFR, the presence, quan-
tity and persistence of C5b-9 in the human disorder may indicate
a worse prognosis [20, 211.
In the present study we investigated the correlation between the
presence of C5b-9 in the urine and the clinical outcome on
patients with IMN and a progressive decline in renal function.
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Methods
Patient selection
The study period was from 1984 to 1993. All adult patients who
had IMN diagnosed by renal biopsy during this period at our
Centre were eligible for consideration. Those included had no
clinical, laboratory or histologic evidence of underlying systemic
disease or occult malignancy, had not been exposed to proven
nephrotoxic drugs and did not have diabetes mellitus. Laboratory
criteria for exclusion were a positive status for antinuclear or
anti-DNA antibody or hepatitis B surface antigen, a positive
VDRL test, or a low level of C3 or C4. Mid-stream urine
specimens were sterile. Patients with signs or symptoms suggestive
of renal vein thrombosis were excluded. Renal venography was
not, however, a requirement in those in whom renal vein throm-
bosis was not suspected. Specific enquiry was undertaken to
exclude exposure to heavy metals and drugs as potential etiolog-
ical agents. Patients treated with immunosuppressive agents other
than prednisolone in the twelve months before entry were ex-
cluded from the study. The duration of disease before the biopsy
was not considered.
Renal histology
A renal biopsy had been undertaken in all patients and had to
contain an adequate number of glomeruli for examination by light
and immunofluorescence microscopy to allow a confident diagno-
sis. The diagnosis of MN was made using the criteria of Churg et
al [22]. The biopsies were not staged. Electron microscopy had
only been performed in biopsies where the diagnosis remained
unclear after light microscopy and immunofluorescence staining.
Study design
All hematological, biochemical and serological investigations
were performed using standard techniques. Urine samples were
collected at each visit. Measurements of proteinuria, serum
albumin and creatinine were made at each clinic visit. Patients
with declining renal function during the study period were con-
sidered for immunosuppressive treatment. If no treatable or
self-limiting causes, such as renal vein thrombosis, were found [14]
and if no contraindication to immunosuppression was present, the
patient's consent was obtained. All patients were rebiopsied if
twelve months had elapsed since their previous biopsy to exclude
diuretic-induced interstitial nephritis [151 and coincident anti-
GBM disease [16]. Biopsies were not routinely performed to
assess the effect of treatment on histopathology. Patients were
assigned in a non-random manner to one of the three treatment
groups.
Treatments
Patients in group Ia received methylprednisolone, 1 g intrave-
nously daily for five days, followed by a tapering dose of oral
prednisolone over eight months. The doses were 100 mg, 75 mg,
50 mg, 25 mg, 20 mg, 15 mg, 10 mg and 5 mg on alternate days for
consecutive four-week periods [10].
Most experience was gained from patients in group Ia. How-
ever, from 1989, patients who relapsed on the above regimen and
new patients with declining renal function were assigned to
treatment groups lb and Ic. Patients in group lb received three
cycles of treatment with methylprednisolone 1 g intravenously
daily for three days and then 0.4 mg/kg/day of oral prednisolone
for 27 days. Each cycle was followed by one month of treatment
with oral chlorambucil (0.2 mg/kg/day). The total duration of
treatment was six months [23].
Patients in group Ic received oral cyclophosphamide (2 mg/kg/
day) for two months followed by a tapering dose of oral pred-
nisolone as in group Ia [24]. They were not given any methyl-
prednisolone. Some patients received cyclophosphamide and
prednisolone concurrently for the first two months, followed by
the same tapering dose of prednisolone.
Anti-hypertensive treatment (including angiotensin-converting
enzyme inhibitor), diuretics, lipid lowering drugs and anticoagu-
lants were given as clinically indicated in all patients.
Definitions
Declining renal function was defined by a sustained rise in
serum creatinine of >30% during the previous twelve month
period. Remission in those with declining renal function, but who
were not given immunosuppressive drugs, was defined as stabili-
zation of serum creatinine so that the value did not continue to
rise >30% by the end of the study period. Patients who received
treatment had one of three clinical outcomes:
(a) Response to treatment. Defined as an improvement in renal
function or stabilization of serum creatinine so that the value did
not continue to rise > 30% by the end of the study period.
(b) Relapse. Defined by a sustained > 30% rise in serum
creatinine over twelve months despite treatment.
(c) ESRF. Defined as a serum creatinine > 0.50 mmol/liter or
dialysis dependency.
Data analysis
Statistical techniques used throughout the study period were as
indicated in the Results section.
Collection of urine samples
Freshly voided urine was collected into EDTA at 4°C, centri-
fuged, aliquoted and stored at —70°C. The creatinine concentra-
tion of the freshly voided urine samples was also determined.
ELISA for C5b-9
This assay was previously described by Brenchley et al [18]. It is
an enhanced chemiluminescence immunoassay which employs the
antibody to C9 neoantigen [25], and is reported to bind both
SC5b-9 and C5b-9. The mAb was coated at 10 tg/ml in 50 mt
carbonate buffer pH 9.6 onto microFLUOR plates (Dynatech)
overnight at 4°C. After blocking, a 1/5 dilution of urine was added
to the wells and incubated overnight at 4°C. Biotinylated goat
anti-C7 (ICN Biomedicals) at 5 tg/ml was left for four hours,
followed by avidin-peroxidase (Sigma) diluted 1/200 for two
hours. Enzyme substrate was added (Amerlite reagent, Kodak)
and the chemiluminescence was detected using a luminometer
(Kodak). A standard containing SC5b-9 was prepared by incubat-
ing fresh normal human serum with zymosan. Arbitrary units of
C5b-9 were read off the standard curve (range =3 to 100 units).
The concentrations of C5b-9 were expressed as a ratio of units per
mg of creatinine in the freshly voided urine sample.
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Table 1. Clinical features of treatment groups Ia, Ib, and Ic
Group Ia
N=13
Group Tb
N=4a
Group IcN=5 P
Age years 51 14.1 49 14.6 52 16.3 >0.05 NS
Sex M:F 9:4
(56%:44%)
3:1
(67%:33%)
4:1
(75%:25%)
> 0.05 NS
Observation 4.1 2.7 3.2 3.5 5.1 3.0 > 0.05 NS
period years
Number of 17 10 17 7 26 15 > 0.05 NS
samples tested
per patient
One patient did not complete the course of treatment but observation
continued and the study was analyzed on an intention-to-treat basis.
All data are mean SD; P, groups Ia vs. Tb vs. Ic (Student's t-test for
age, observation period and number of samples tested per patient, and chi
squared test for sex).
Results
Patients and clinical features
Thirty-five patients had declining renal function during the
study period: eighteen patients received immunosuppressive
treatment (group I) while 17 patients did not (group II). Of the
eighteen treated patients, three received more than one treatment
regimen because of clinical relapse; the same two patients ap-
peared in Groups Ia and Ic, and the third patient received three
regimens at different time points. Hence twenty-two treatments
were available for analysis. The groups were: group I treatment
group (N = 22) comprised (a) prednisolone alone (N = 13), (b)
prednisolone and chlorambucil (N =4), and (c) prednisolone and
cyclophosphamide (N = 5); group II was the non-treatment
control group (N = 17).
Table 1 shows the clinical features of the three treatment
groups Ia-Ic. The ages shown were at the start of treatment. The
observation period was taken from the date of the first to the last
available uC5b-9 sample. There was no significant difference in
the age, sex, the observation period and the number of samples
tested between the three groups. All these patients were com-
bined together in one group (group I) in subsequent analysis since
the clinical data were similar in the three groups irrespective of
treatment regimen, and small numbers were involved in groups lb
and Ic. There was only one withdrawal in this study. This patient
did not complete the course of prednisolone and chlorambucil
because of nausea and vomiting. Observation was continued and
the study was analyzed on an intention-to-treat basis.
Table 2 shows clinical features and laboratory data of groups I
and II. The ages shown were at the time of the first available
uC5b-9 sample. The observation period was taken from the date
of the first to the last available uC5b-9 sample. There was no
significant difference in the age, sex distribution or the observation
period between the two groups. The seventeen patients with
declining renal function did not receive immunosuppressive drugs
(group II) because of clinical contraindications: two reached
ESRF soon after diagnosis, two had recently undergone coronary
bypass grafting, three had acute myocardial infarctions, one had
recurrent peptic ulceration, one had a stroke, two were more than
70 years of age, two had benign prostate hyperplasia and required
surgical intervention, one had moved away from the area, two
were deemed non-compliant, one died of non-renal cause while
under consideration, and for two the reason was uncertain.
Table 2. Clinical features and laboratory data of group I (treatment)
and group II (non-treatment)
Group I
N=18 Group IIN=17 P
Age years 51 16.3 56 12.1 >0.05 NS
Sex (M:F) 14:4 16:3 > 0.05 NS
Observation period
(78%:22%)
4.1 3.5
(84%:16%)
5.0 3.4 > 0.05 NS
years
Serum creatinine
mmol/liter'
before RxJstart of 0.300" 0.129c ND
observation
period
after Rx/end of 0200" 0.240c ND
observation
period
Proteinuria
g/24 hra
before Rx/start of 14.0" 6.2 ND
observation
period
after Rx/end of 70d 5.0" ND
observation
period
Data for age, sex and observation period are mean s; data for serum
creatinine and proteinuria are median values; P group I vs. group II
(Student's t-test for age and observation period, chi square test for sex);
Rx, treatment; ND, not done.
a Two patients excluded from analysis as they reached end-stage renal
failure
h,c,d P < 0.05 and "p> 0.05 NS, serum creatinine and proteinuria before
vs. after Rx in group I, and the start vs. end of the observation period in
group II (Wilcoxon test)
Laboratory data
The data in Table 2 were expressed in median values as the
distribution of serum creatinine and proteinuria data were non-
parametric. There was a significant increase in serum creatinine
(0.129 mmol/liter vs. 0.240 mmol/liter) without a significant fall in
proteinuria (6.2 g124 hr vs. 5.0 g124 hr) by the end of the
observation period in group II. In group I, values were taken
before and after treatment, respectively, which best reflects the
effect of treatment. In group I, the serum creatinine improved
significantly (P < 0.05) from a pretreatment value of 0.300
mmol/liter to a post-treatment value of 0.200 mmol/liter, with a
decrease in proteinuria from 14 g!24 hr to 7 g/24 hr (P < 0.05).
Two patients in group I progressed to ESRF despite treatment.
Their pre- and post-treatment serum creatinine and proteinuria
values were therefore excluded from the statistical analysis of
group I. The difference in serum creatinine and proteinuria
between the two groups was not subjected to statistical analysis
because the data in group I were taken just before the start of
treatment, having observed a sustained rise in serum creatinine of
> 30% during the previous twelve month period, while the data
for group II were taken from the beginning of the observation
period.
Urinary C5b-9 results
Urinary C5b-9 was being excreted before treatment in 18 of the
22 treatment cycles. All the 17 patients in group II were excreting
C5b-9 at the beginning of the study period. Table 3 shows the final
uC5b-9 excretory status in groups I and II at the end of the
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Table 3. Urinary C5b-9 excretory status at the end of the observation
period in all patients who were initially excreting C5b-9 (N = 35)
Number of patients
Final urinary C5b-9
excretory status
positive negative
Group I—treatment (N = 18) 7 11
Group Il—non-treatment (N = 17) 10 7
P > 0.05 NS (Fisher's exact test)
observation period. There was no significant difference in C5b-9
excretory status in the treatment group compared to the non-
treatment group. The effect of treatment on uC5b-9 excretion may
have been obscured because the final uC5b-9 excretory status was
taken at the end of the observation period rather than at the end
of treatment, In this study, four patients became negative on
treatment but resumed excreting C5b-9 after treatment had been
discontinued.
Group II may be a worse prognostic group because many had
atherosclerotic disease and immunosuppressive treatment was
therefore contraindicated. Because this was not a randomized
trial, the clinical outcome of the patients in groups I and II was
analyzed together in association with the final uC5b-9 excretory
status. Table 4 shows the clinical outcome of all thirty-five patients
(drawn from groups I and II) who were excreting C5b-9 initially.
Seventeen patients continued to excrete C5b-9 and 18 had
stopped excretion at the end of the study period. Among the 17
persistent excretors, twelve had either relapsed or had progressed
to ESRF, and five went into spontaneous remission and followed
a stable clinical course. Of the 18 patients who ceased to excrete
C5b-9, sixteen either showed a clinical response to treatment (9
from group I) or had a subsequent spontaneous remission (7 from
group II). Only two patients who became negative for uC5b-9 had
a poor clinical outcome: one progressed to ESRF and the other
had a subsequent relapse (both from group I). Renal function was
more impaired in group I before the commencement of treatment
(serum creatinine 0.300 mmol/liter) than in group II at the end of
the study period (serum creatinine 0.240 mmol!liter). Clinical
outcomes, rather than serum creatinine, were used to compare the
persistent uC5b-9 excretors with those who ceased to excrete, as
progression to ESRF would skew any comparison of serum
creatinine levels. When clinical outcomes were compared, those
who continued to excrete C5b-9 were significantly more likely to
relapse or progress to ESRF than those who ceased excretion
(Fisher's exact test P < 0.005).
Protein excretion was also analyzed in association with the final
uC5b-9 excretory status. Protein excretion was significantly lower
in the eighteen patients who stopped excreting C5b-9 (proteinuria
4.7 g/24 hr) than in the seventeen persistent excretors (proteinuria
9.6 g/24 hr; Wilcoxon test P < 0.05).
Discussion
The clinical course of patients with IMN is variable and
progression to ESRF varies from 25% to 50% [2]. Perhaps
because of this variability, the results of treatment with various
therapeutic regimens remain contentious. Once progressive de-
cline in GFR ensues, in the absence of treatable or self-limiting
causes, renal function invariably proceeds to ESRF [26].
There is thus a need to identify patients in whom there is
Table 4. Clinical outcome of all patients who were initially excreting
C5b-9 (N = 35)
Clinical outcome
Final urinary C5b-9
excretory status
positive negative
Number of patients
Response to treatment/remission
Relapse/end stage renal failure
5 16
12 2
Total 17 18
P < 0.005 (Fisher's exact test)
evidence of on-going immunological insult which may indicate
current or potential progression. Prior to the current studies on
urinary complement components, the only putative markers of
ongoing glomerular injury were measurements of GFR and
proteinuria. Complement activation products have been detected
in body fluids and correlated with activity in other disease states,
such as systemic lupus erythematosus and rheumatoid arthritis
[27, 28]. A number of studies have documented the detection of
complement activation products in plasma and urine in human
glomerular disease. In IgA nephropathy, plasma C3d fragments
correlated with markers of disease activity [29], which may reflect
complement activation in the mesangium as opposed to a subep-
ithelial site in MN. Brenchley et al [18] have previously described
a correlation between C5b-9 excretion and clinical course in
cross-sectional analyses. Elevated uC5b-9 in a subset of patients
with IMN or lupus MN has been reported [17], while others have
correlated uC5b-9 with proteinuria [30, 31] and the intensity of
immunofluorescence on biopsy [32]. In this study, C5b-9 excretion
did not correlate with proteinuria.
This non-randomized prospective trial was to correlate the
excretion of C5b-9 and clinical outcome. Treatment was given to
eighteen patients with any degree of persistent proteinuria who
developed renal impairment. Focusing on these patients with a
poor long-term prognosis improved the likelihood of demonstrat-
ing a statistically significant effect of treatment, and also provided
adequate justification for the use of potentially toxic therapy. To
avoid the problems of disease variability, patients served as their
own controls. To qualify for treatment, each patient had to have
had at least six months of documented progressive renal dysfunc-
tion. This selection process eliminated those patients who might
have remitted spontaneously as well as those who might have
stable renal dysfunction. Furthermore, there was a control group
with declining renal function who did not receive immunosuppres-
sive drugs because of clinical contraindications. Patients excreting
C5b-9 had a better clinical outcome if they stopped excreting
C5b-9. This cohort also had less proteinuria. A policy of waiting
for two to three years for those with declining renal function to
identify themselves unequivocally carries with it the risk that early
events, which might irrevocably determine prognosis, will be
missed. However, a third of patients with IMN remit spontane-
ously and this cohort is unlikely to benefit from treatment [2].
Thus there is a need to identify patients in whom there is evidence
of ongoing immunological insult in IMN and C5b-9 excretion
appears to be a dynamic marker.
It is likely that patients with evidence of current progression are
the ones who may benefit most from immunosuppressive drugs.
The question then arises as to what treatment to use. This study
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did not answer the question as the uC5b-9 did not fall significantly
in the treatment group. Only the treatment effect of prednisolone
was examined because of the small numbers in groups lb and Ic.
The benefit of adding either of the alkylating agents could not be
answered for the same reason. The elimination of C5b-9 excretion
would seem to be a useful end-point in determining the efficacy of
treatment, although this could not be shown conclusively from our
study. If, as seems to be the case, persistent C5b-9 excretion is a
marker for poor prognosis, the use of more toxic or more lengthy
immunosuppressive protocols may be justified in this group. A
rational approach may be to commence treatment with cortico-
steroids and to add an alkylating agent if C5b-9 was still being
excreted after a certain period. Persistence of excretion despite
treatment may be used to justify either longer or higher dose
regimens of alkylating agents. Thus therapy could be tailored to
the individual patient in a more rational manner.
The mechanisms by which these immunosuppressive drugs
suppress or eradicate the excretion of C5b-9 are unknown. They
do not appear to block the complement cascade. These drugs may
affect the cell biology of the glomerular epithelial cell (GEC), so
that the GEC can eliminate membrane attack complex (MAC) by
one of several ways as demonstrated in the animal model. GEC in
the rat have been shown in vitro to exocytose MAC following
vesiculation of the complex [33], and GEC in vivo were able to
endocytose glomerular deposits of C5b-9, which were transported
transcellularly to be exocytosed into the urinary space [341.
This study shows that uC5b-9 is a marker of ongoing immuno-
logical insult in IMN and is potentially useful in the selection of
patients for treatment and in monitoring the efficacy of treatment
on the activity of this disease.
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